SCHEMBL7868149

SCHEMBL7868149

COc1ccc(-c2ccc(C(CC=O)C(=O)O)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.49
AKR1C3 P42330 4/20 0.48
AKR1C2 P52895 4/20 0.48
AKR1C1 Q04828 1/20 0.48
PTGS1 P23219 1/20 0.48
LDHA P00338 1/20 0.45
CCKAR P32238 4/20 0.45
ALOX5 P09917 1/20 0.44
APP P05067 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP17A1 P05093 1/20 0.43
GPR88 Q9GZN0 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP12 P39900 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893011 0.95 AKR1C3 (0.51) FFAR1AKR1C3AKR1C2AKR1C1PTGS1
SCHEMBL6931563 0.85 RAB9A (0.59)
SCHEMBL7347852 0.82 CYP2C19 (0.56) FFAR1PTGS1CYP2C19
SCHEMBL14445129 0.81 CYP2C19 (0.65) FFAR1AKR1C3AKR1C2AKR1C1PTGS1
SCHEMBL8153620 0.79 THRB (0.49) AKR1C3AKR1C2AKR1C1PTGS1LDHA
SCHEMBL16893443 0.79 ALOX15 (0.45) AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1
SCHEMBL3910474 0.79 GAA (0.60) FFAR1AKR1C3AKR1C2AKR1C1PTGS1
SCHEMBL5310005 0.78 AKR1C3 (0.50) AKR1C3AKR1C2AKR1C1PTGS1CCKAR
SCHEMBL490727 0.77 AKR1C3 (0.55) FFAR1AKR1C3AKR1C2AKR1C1PTGS1
SCHEMBL22095156 0.77 AKR1C3 (0.73) FFAR1AKR1C3AKR1C2AKR1C1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6307089-B2 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-10-23 US disclosed
US-6239288-B1 RHEUMATIC DISEASES WARNER-LAMBERT COMPANY 2001-05-29 US disclosed
US-20010000513-A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-04-26 US disclosed
EP-0927156-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1999-07-07 EP disclosed
WO-1998009940-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000513-A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP26, MMP1, MMP9 FFAR1 515/4885AKR1C3 788/4885AKR1C2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.